PSYK
The World’s First Psychedelics ETF
Within the last decade, there has been a significant re-evaluation of the potential therapeutic benefits of psychedelics, and a movement to research these substances and potentially use them for therapeutic use, particularly in the treatment of mental health issues. Horizons Psychedelic Stock Index ETF (PSYK) is the world’s first psychedelics-focused ETF providing investors a new way to get exposure to this emerging healthcare sector.
North American Psychedelics Index
Constituents are listed on North American exchanges and are publicly listed life sciences companies focused on psychedelic medicine, and other companies with business activities in the psychedelics industry. While securities may be listed on the TSX, NYSE or Nasdaq Global Market, many of these securities may trade on North American junior exchanges that include (but are not limited to) the:
• TSX Venture Exchange
• Canadian Securities Exchange
• NEO Exchange
• NASDAQ Stock Market
• NYSE American
Investment Objective
PSYK seeks to replicate, to the extent possible and net of expenses, the performance of a market index that is designed to provide exposure to the performance of a basket of North American publicly-listed life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry. Currently, the ETF seeks to replicate the performance of the North American Psychedelics Index, net of expenses.
Fund Details
The NAV chart above only shows the historical daily net asset value per unit (NAV) of the ETF, and identifies the various distributions made by the ETF, if any. The distributions are not treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses. The chart is not a performance chart and is not indicative of future NAV values which will vary.
The Growth of 10K chart above is based on the historical daily net asset value per unit (NAV) of the ETF, and represents the value of an initial investment into the ETF of $10,000 since its inception, on a total return basis. Distributions, if any, are treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses where paid by the fund. The chart is not a performance chart and is not indicative of future value which will vary.
Annualized Performance (%) *
1mo | 3mo | 6mo | YTD | 1 yr | 3 yr | 5 yr | 10 yr | SIR** | |
---|---|---|---|---|---|---|---|---|---|
Horizons Psychedelic Stock Index ETF | 0.66 | -6.59 | -47.10 | 11.18 | -48.26 | -- | -- | -- | -54.75 | North American Psychedelics Index | 1.87 | -3.27 | -44.42 | 15.14 | -44.97 | -- | -- | -- | -53.89 |
**Fund performance since inception on January 26, 2021, as at February 28, 2023
Calendar Year Performance (%) *
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|---|---|---|
Horizons Psychedelic Stock Index ETF |
-- | -- | -- | -- | -- | -- | -- | -63.48 | North American Psychedelics Index | -- | -- | -- | -- | -- | -- | -- | -62.93 |
Distributions
Year | Ex-Dividend Date | Record Date | Payment Date | Payment Amount | Reinvested Non-Cash Distributions | Distribution Period |
---|---|---|---|---|---|---|
2021 | 09/28/2021 | 09/29/2021 | 10/13/2021 | 0.03023 | — |
Top 10 Holdings
As at March 10, 2023Security Name | Weight |
---|---|
MIND MEDICINE MINDMED INC | 14.78% |
CYBIN INC . | 12.33% |
GH RESEARCH PLC . | 9.28% |
COMPASS PATHWAYS PLC ADR | 9.12% |
Numinus Wellness Inc | 8.56% |
SEELOS THERAPEUTICS INC . | 8.52% |
Relmada Therapeutics Inc | 8.10% |
Revive Therapeutics Ltd | 6.89% |
Abbvie Inc | 6.03% |
Johnson & Johnson | 5.60% |
Holdings are subject to change. Download full prior business day: Holdings
Education
Regulatory and Legal
The World’s First Psychedelics ETF
Within the last decade, there has been a significant re-evaluation of the potential therapeutic benefits of psychedelics, and a movement to research these substances and potentially use them for therapeutic use, particularly in the treatment of mental health issues. Horizons Psychedelic Stock Index ETF (PSYK) is the world’s first psychedelics-focused ETF providing investors a new way to get exposure to this emerging healthcare sector.
North American Psychedelics Index
Constituents are listed on North American exchanges and are publicly listed life sciences companies focused on psychedelic medicine, and other companies with business activities in the psychedelics industry. While securities may be listed on the TSX, NYSE or Nasdaq Global Market, many of these securities may trade on North American junior exchanges that include (but are not limited to) the:
• TSX Venture Exchange
• Canadian Securities Exchange
• NEO Exchange
• NASDAQ Stock Market
• NYSE American
Investment Objective
PSYK seeks to replicate, to the extent possible and net of expenses, the performance of a market index that is designed to provide exposure to the performance of a basket of North American publicly-listed life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry. Currently, the ETF seeks to replicate the performance of the North American Psychedelics Index, net of expenses.
Fund Details
The NAV chart above only shows the historical daily net asset value per unit (NAV) of the ETF, and identifies the various distributions made by the ETF, if any. The distributions are not treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses. The chart is not a performance chart and is not indicative of future NAV values which will vary.
The Growth of 10K chart above is based on the historical daily net asset value per unit (NAV) of the ETF, and represents the value of an initial investment into the ETF of $10,000 since its inception, on a total return basis. Distributions, if any, are treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses where paid by the fund. The chart is not a performance chart and is not indicative of future value which will vary.
Annualized Performance (%) *
1mo | 3mo | 6mo | YTD | 1 yr | 3 yr | 5 yr | 10 yr | SIR** | |
---|---|---|---|---|---|---|---|---|---|
Horizons Psychedelic Stock Index ETF | 0.66 | -6.59 | -47.10 | 11.18 | -48.26 | -- | -- | -- | -54.75 | North American Psychedelics Index | 1.87 | -3.27 | -44.42 | 15.14 | -44.97 | -- | -- | -- | -53.89 |
**Fund performance since inception on January 26, 2021, as at February 28, 2023
Calendar Year Performance (%)
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|---|---|---|
Horizons Psychedelic Stock Index ETF | -- | -- | -- | -- | -- | -- | -- | -63.48 | North American Psychedelics Index | -- | -- | -- | -- | -- | -- | -- | -62.93 |
Distributions
Year | Ex-Dividend Date | Record Date | Payment Date | Payment Amount | Reinvested Non-Cash Distributions | Distribution Period |
---|---|---|---|---|---|---|
2021 | 09/28/2021 | 09/29/2021 | 10/13/2021 | 0.03023 |
Top 10 Holdings
As at March 10, 2023Security Name | Weight |
---|---|
MIND MEDICINE MINDMED INC | 14.78% |
CYBIN INC . | 12.33% |
GH RESEARCH PLC . | 9.28% |
COMPASS PATHWAYS PLC ADR | 9.12% |
Numinus Wellness Inc | 8.56% |
SEELOS THERAPEUTICS INC . | 8.52% |
Relmada Therapeutics Inc | 8.10% |
Revive Therapeutics Ltd | 6.89% |
Abbvie Inc | 6.03% |
Johnson & Johnson | 5.60% |
Holdings are subject to change. Download full prior business day: Holdings